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Background: Hyperandrogenism is the primary manifestation of polycystic ovary syndrome (PCOS), which appears
to be caused by excess exposure to androgen. As such, androgenized animal models have been developed and
investigated to study the etiology of PCOS. Anti-Mullerian hormone (AMH) is known to be associated with follicle
growth, and its levels are two to three times higher in women with PCOS than in those with normal ovaries.
We studied how duration of androgen administration affects folliculogenesis and AMH expression.
Methods: We divided 30 immature (3-week-old) Sprague Dawley rats into six groups. Three groups were injected
each evening with dehydroepiandrosterone (DHEA) (6 mg/100 g body weight/0.2 ml sesame oil) for 7, 15 or
30 days, respectively. The three control groups were injected with 0.2 ml of sesame oil for the corresponding
lengths of time. Resected ovaries were sectioned and examined to determine follicle numbers at each
developmental stage, and immunostained to assess AMH expression.
Results: On day 7, follicle numbers and AMH expression levels at each developmental stage of follicle growth were
similar in the respective control and DHEA groups. On day 15, the total follicle number (P = 0.041), the percentage
of primordial follicles (P = 0.039) and AMH expression were significantly greater in the DHEA than the control group.
On day 30, the percentages of primordial (P = 0.005), primary (P = 0.0002) and atretic (P = 0.03) follicles were
significantly greater in the DHEA group, whereas the percentage of intermediary follicles (early pre-antral, late
preantral, and early antral follicles) was significantly lower in the DHEA group (P = <0.0001). AMH expression in
DHEA-treated rats on day 30 was seen exclusively in the primordial (P = 0.0413) and late antral follicles (p = 0.028).
Conclusions: Androgen administration increases AMH production in a process that regulates the growth of
primordial follicles. That is, androgen-induced AMH expression provides local negative feedback to folliculogenesis
augmented by androgen.
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Polycystic ovary syndrome (PCOS) is the most common
endocrine-metabolic dysfunction in women of reproduct-
ive age, and a frequent cause of anovulatory infertility and
hyperandrogenism [1]. The polycystic ovary (PCO)
morphology in PCOS is characterized by an excessive
number of growing follicles, suggesting folliculogenesis is* Correspondence: tbaba@sapmed.ac.jp
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mary manifestation of PCOS, and it is the excess androgen
exposure that appears to be the cause of the PCO morph-
ology. However, we have shown that long-term adminis-
tration of androgens for female-to-male transsexual
(FTM) persons leads to an increase in the number of
atretic follicles, not to the PCO morphology [3].
Several androgenized animal models have been devel-
oped and investigated to determine the etiology of PCOS.
Slight differences among the models reflect differences intd. This is an Open Access article distributed under the terms of the Creative
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as well as the amount of hormone administered [4-6].
Nearly all animals administered androgen during fetal
life exhibit PCO and show endocrine abnormalities
similar to PCOS [4,7]. In a report on the effects of an-
drogen administration to immature rats, short-term
treatment caused PCO morphology, while medium-
term treatment resulted in an increase in follicle atresia
[6]. In another study, reproductive-age rhesus monkeys
receiving high doses of androgen in the short-term were
equally as likely to exhibit an increase in small follicles
as monkeys receiving low doses over a longer term [5].
In addition, examination of the histology of ovaries in
androgen-administered FTM patients revealed in-
creased follicular atresia, though the morphogenesis of
polycystic ovaries is controversial [3,8,9]. Judging from
these findings, it appears that androgen administration
may impact folliculogenesis and subsequent ovarian
morphology, leading to the development of the PCO
morphology, but the effects of exogenous androgens on
ovarian morphology may vary depending on the period
and duration of the androgen administration and the
amount of hormone administered. In other words,
androgen-induced PCO morphology may be a time-
lapse snapshot of metamorphosis.
Because the effect of androgen is not constant, other
factors modifying its effects on folliculogenesis may
exist. For example, we have been particularly interested
in anti-Mullerian hormone (AMH), which is known to
be associated with follicle growth. AMH is produced by
granulosa cells in early developing follicles and inhibits
the transition from the primordial to the primary follicu-
lar stage. AMH levels can be measured in serum and
have been shown to be proportional to the number of
small antral follicles [10]. In women with PCOS, serum
AMH levels are two to three times higher than in
women with normal ovaries [11]. This is thought to be
due to the large number of small antral follicles as well
as enhancement of the AMH production per granulosa
cell [12]. On the other hand, Stubbs et al. reported that
primordial follicles only weakly express AMH, and that
expression levels of AMH in primordial follicles in
PCOS are lower than in the control [13]. In addition,
prenatally androgenized sheep, which manifest PCOS-
like features, exhibited reduced AMH expression by pre-
antral and antral follicles [14]. In PCOS, the relationship
between hyperandrogenism and AMH remains unclear.
It is thought, however, that androgen and AMH are
closely related, and both affect folliculogenesis.
In the present study, we sought to determine the effect
of the duration of androgen administration on folliculo-
genesis and AMH expression using a juvenile rat model.
Our primary aim was to clarify the roles of androgen
and AMH in the pathogenesis of PCOS.Methods
Animals and treatments
The study was carried out using 30 immature (3-week-
old) Sprague Dawley rats, with body weights of 35–40 g
and regular (4–5 days) ovulatory cycles. The rats were
injected (subcutaneously) with dehydroepiandrosterone
(DHEA; Wako Hormone Manufactory Co., Tokyo,
Japan) (6 mg/100 g body weight/0.2 ml sesame oil) each
evening for 7,15 or 30 days (7-, 15- and 30-day DHEA
groups, respectively). Control rats were injected with
0.2 ml of sesame oil each evening for the corresponding
lengths of time (7-, 15- and 30-day control groups, re-
spectively) [6,15]. Rats were sacrificed by decapitation
on the evening of day 8, 16 or 31. Animals used in this
study were maintained in accordance with the guidelines
of the Animal Resources Centre of the Sapporo Medical
University School of Medicine.
Immunohistochemistry
For immunohistochemical analysis, ovaries were dis-
sected, weighed, fixed in 10% formalin, embedded in
paraffin, and serially sectioned longitudinally throughout
the largest diameter of the ovaries (thickness, 7 μm). One
slice from each ovary was stained with hematoxylin-eosin
for a follicle count. Then after deparaffinization in xylene
and rehydration through an ethanol series, the other sec-
tions were placed on slides, and AMH expression was de-
tected immunohistochemically. Initially, antigens were
retrieved using Histo VT one (10×, pH 7.0; Nacalai
Tesque, Inc., Kyoto, Japan), and nonspecific antibody
binding was reduced by incubation for 60 min with 1%
normal rabbit serum in PBS. The primary antibody, goat
anti-human AMH (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), was diluted 1:50 in PBS containing 1%
normal rabbit serum and incubated with the sections
overnight at 4°C. Thereafter, the sections were incu-
bated for 30 min with biotinylated secondary antibody,
followed by incubation with ABC reagent (Vectastain
ABC Kit, Vector Laboratories, CA, USA) for 5 min at
room temperature. Diaminobenzidine (DAB) was used
as a chromogen (Peroxidase Stain DAB Kit, Nacalai
Tesque, Inc., Kyoto, Japan). The sections were counter-
stained with Mayer’s hematoxylin.
Morphological classification and analysis
A single investigator blinded to the weekly age and treat-
ment of the rats assessed the follicle number and the
presence or absence of staining. The numbers of follicles
at each developmental stage in each group were esti-
mated by counting follicles in each section per individ-
ual. The criteria used for classifying the developmental
stages of follicles were as follows: 1) primordial follicle,
oocyte surrounded by a single squamous layer of follicu-
lar somatic cells; 2) primary follicle, a single layer of
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to four layers of granulosa cells; 4) late preantral follicle,
more than four layers of granulosa cells and no antrum;
5) early antral follicle, contains an antrum and the fol-
licle diameter is < 220 μm; 6) late antral follicle, contains
an antrum and the follicle diameter is > 220 μm; 7)
atretic follicle, contains a degenerate oocyte, an oocyte
that has resumed meiosis, or cumulus cells dissociated
from the oocyte, and pyknotic granulosa cells are com-
mon [16].
AMH staining was assessed only in healthy follicles.
Atretic follicles with pyknotic granulosa cells or oocytes
were excluded from immunohistochemical analysis. The
intensity of AMH staining was determined on screen
using a printed example of each follicle for relative com-
parison, and was classified according to the following
criteria: −, no staining; ±, mild to moderate staining;
and +, strong staining (Figure 1-G-I). To calculate the
AMH staining score, − = 0, ± = 1, and + = 2. The calcu-
lated scores per 100 follicles in the DHEA and control
groups were compared.
Statistical analysis
Data were analyzed using Excel Statistics, 2009 (OMS
publishing company, Tokorozawa, Japan). The quantita-
tive results (follicle number and hormonal parameters)
are presented as median [interquartile range (IQR)] and
were compared using nonparametric analysis (Mann–
Whitney U test). The proportions (the percentage of fol-
licles at each stage and the percentage of follicles ex-
pressing AMH) and AMH expression scores were
compared using the χ2 test.
Results
Histopathological analysis
The macroscopic ovarian findings on day 7 were similar
in both the DHEA and control groups (Figure 1A, D).
On day 15, by contrast, ovaries in the DHEA group ex-
hibited PCO morphology (Figure 1E), but the control
group did not (Figure 1B). Ovaries also showed PCO-
like morphology in the day-30 DHEA group, but with
larger cystic follicles than were seen on day 15 (Figure 1E,
F). In the day-30 control group, ovaries had fewer follicles
than in other groups (Figure 1C). On days 7 and 15
(juvenile period), ovary volumes and weights were similar
in the DHEA and control groups. On day 30 (pubertal
period), by contrast, ovary volumes and weights in the
DHEA group were smaller than in the control group.
Ovaries in the day-30 DHEA group showed no increase in
weight, as compared to the day-15 DHEA group, despite
an increase in overall body weight (Figure 2A).
Approximately 1773 follicles were examined in 30 sec-
tions from the ovaries of the 30 rats. In the day-7
groups, total follicle number and the percentages offollicles at each developmental stage were similar
(Figure 2B-F). In the day 15 groups, total follicle num-
ber (P = 0.041, Figure 2B) and the percentage of primor-
dial follicles (P = 0.039, Figure 2C) were significantly
greater in the DHEA group than the control group. In
the day 30 groups, total follicle numbers were similar
in the DHEA and control groups (Figure 2B), but the
percentages of primordial (P = 0.005, Figure 2C), primary
(P = 0.0002, Figure 2D) and atretic (P = 0.03, Figure 2F)
follicles were significantly larger in the DHEA group,
while the percentage of intermediary follicles (early pre-
antral, late preantral, and early antral follicles) was sig-
nificantly smaller in the DHEA group than the control
group (P < 0.0001, Figure 2E).
Immunolocalization of AMH
AMH is expressed in granulosa cells. Although oocyte
morphology was poorly preserved in these formalin-
fixed sections, AMH immunostaining was detected in
more than half of the oocytes. Low levels of AMH stain-
ing were detected in primordial follicles (Figure 1G, H),
and a very small number of follicles showed strong stain-
ing (Figure 1G). Mild to moderate staining was observed
in more than half of the primary follicles (Figure 1J),
while moderate to strong staining was observed in a ma-
jority of intermediary follicles (early preantral, late pre-
antral, and early antral) (Figure 1K, L), though expression
was diminished in late antral follicles. Atretic follicles ex-
hibited irregular staining of the granulosa cells still adher-
ing to the basal lamina (data not shown).
The intensity of AMH staining in the day-7 groups was
similar at all follicular developmental stages (Figure 3A).
In the day-15 groups, the intensity of staining in the
DHEA-treated ovaries was significantly greater in the
primordial (P= 0.0079), primary (P = 0.026), early pre-
antral (P = 0.0001), late preantral (P = 0.0014), early an-
tral (p = −0.0048) and late antral (P = 0.0001) follicles
(Figure 3B). In the day 30 groups, the intensity of stain-
ing in the DHEA group was much greater than control
at the primordial (P = 0.0485) and late antral (P =
0.0028) stages.
Hormone assay
As shown in Table 1, the serum androstendione levels
were higher in the DHEA group than the control group
on days 15 (P = 0.009) and 30 (P = 0.005). The serum
DHEA-S levels were higher in DHEA-treated than con-
trols rats on all days (day 7: P = 0.004, day15: P = 0.009,
and day 30: P = 0.009). Serum AMH levels were signifi-
cantly higher than control in the DHEA group on day
15 (P = 0.04), but were similar in the two groups on days
7 (P = 0.56) and 30 (P = 0.11). AMH values tended to be
higher in the DHEA group on day 7, whereas they















Figure 1 Ovaries and follicles immunostained for AMH in DHEA-treated and control rats. (A ~ F) Light micrographs of hematoxylin/
eosin-stained whole rat ovary sections: vehicle (control) administration for 7 days (A), 15 days (B) or 30 days (C); DHEA administration for 7 days
(D), 15 days (E) or 30 days (F). At 7 days, the ovaries of both groups (A, D) contain numerous follicles and were similar in configuration. The
day-15 DHEA ovary has more small follicles than control ovaries (B, E) and exhibits a polycystic-like morphology. Day-30 control ovaries have
fewer follicles than any of the other groups (C). Day 0-30 DHEA ovaries have more cystic follicles than ovaries of the day-30 control and day-15
DHEA groups (C, E, F). These micrographs are at different magnifications. (G ~ L) AMH immunostaining in ovaries from DHEA-treated and control
rats: (G) Strong diffuse expression of AMH (+) in primordial follicles; (H) Mild sparse expression (±) in primordial follicles; (I) No expression (−) in
primordial follicles; (J) Strong expression in primary the follicles; (K) Moderate expression in the late preantral follicles; (L) Strong expression in
early antral follicles.
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In this study, we found that by day 7, DHEA treatment
had caused a slight increase in follicle numbers and
serum AMH levels, but it had not affected AMH expres-
sion. It is well known that androgens that promote fol-
licle growth most strongly affect preantral to early antralfolliculogenesis [17], and it also reportedly stimulates
transition from primary to secondary follicles [18]. We
speculate that with brief treatment, androgen stimulates
follicle development, but does not affect AMH produc-
tion in granulosa cells. The slight elevation of serum
AMH level reflects a slight increase in follicle number.
Figure 2 Comparison of ovarian area, follicle numbers and follicles at each stage. (A) Mean ovarian volume (mm2) in DHEA-treated vs. un-
treated ovaries. The height, major axis and minor axis of each ovary were measured in 0.01 mm increments; ovarian volumes were then calcu-
lated using the formula, Volume = (4 π a b c) / 3, where a = height, b = length of the major axis, and c = length of the minor axis. Values are
medians ± 95% confidence intervals of the median. Average ovarian volumes were significantly smaller than control in the day-30 DHEA group.
(B) Total number follicle numbers were significantly higher than control in the day-15 DHEA group. (C) Percentages of primordial follicles were
significantly higher than control in the day-15 and day-30 DHEA groups. (D) Percentages of primary follicles were significantly higher than control
in the day-30 DHEA group. E) Percentages of intermediary follicles (early preantral, late preantral and early antral) were significantly lower than
control in the day-30 DHEA group. (F) Percentages of atretic follicles were significantly higher than control in the day-30 DHEA group.
*P < 0.05; **P < 0.01.
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remarkable changes in the ovaries. Fifteen days of DHEA
treatment led to a significant increase in total follicle
number and AMH expression in the ovaries, and to sig-
nificantly greater serum AMH levels. We suggest that
the elevation of serum AMH is caused by not only an in-
crease in the number of intermediary follicles, but also
by augmented production of AMH in granulosa cells.
The increased AMH production is also observed in
PCOS [19], which supports the premise that the elevated
AMH in PCOS is caused by hyperandrogenemia. Fur-
thermore, the increased AMH changed the folliculogen-
esis. In early follicle development, AMH reduces
primordial and primary follicle growth and prevents de-
pletion of any follicle cohort [10]. We observed that by
day15, the increased AMH had inhibited primordial fol-
licle growth, but that follicular development at stages
later than primary follicles was maintained by the effect
of DHEA. As a result, total follicle number and the pro-
portion of primordial follicles were increased. Although
the proportion of intermediary follicles was unchanged,
the actual number of intermediary follicles was increased
due to the increase in the total follicle number.Consequently, serum AMH should be elevated. Had the
elevation in AMH not occurred, follicular development
would not have been inhibited, and the follicles would
have become depleted [20]. AMH is therefore thought
to control the androgen effect on follicular growth.
Long-term treatment caused further morphological
changes and led to atresia and atrophy. Thirty days of
DHEA treatment caused an increase in the percentages
of primordial, primary and atretic follicles, and a de-
crease in the percentage of intermediary follicles. AMH
also reportedly reduces primary follicle growth [21], and
we found that growth of primary and primordial follicles
was impaired by increased AMH. DHEA would be ex-
pected to encourage intermediary follicles to grow to the
next stage, but to provide fewer follicles at the inter-
mediary stage. A decrease in the number of intermediary
follicles would be expected to reduce serum AMH levels;
however, we observed that the reduction in serum AMH
was minimal with respect to the decrease in the number
of intermediary follicles, because the expressed AMH
produced earlier in granulosa cells persisted.
Androgens may regulate follicular atresia [22]; for ex-











































































































































Figure 3 Comparison of ovarian AMH immunostaining in DHEA-treated and control rats. AMH was detected immunohistochemically and
scored as described in the Methods. (A) AMH staining in the day-7 DHEA and control groups. (B) AMH staining in the day-15 DHEA and control
groups. (C) AMH staining in the day-30 DHEA and control groups. (D) Percentages of primordial follicles expressing AMH at the indicated levels.
Staining intensity was significantly greater than control in the day-15 and day-30 DHEA groups. *P < 0.05; **P < 0.01.
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apoptotic effects of estradiol in rat granulosa cells in
early antral and preantral follicles [24]. However, it was
recently reported that androgens also exert an anti-
apoptotic effect [25,26]. Thus the relationship between
androgens and atresia appears complex. In human stud-
ies, increases in the numbers of atretic follicles were ob-
served in the ovaries of androgen-administrated FTM
persons [3,8,9]. The treatment periods were fairly long,
averaging 38 months [3], 21 months [8] and 35 months
[9], respectively. Consistent with those reports, we ob-
served increases in the numbers of atretic follicles with
long-term DHEA treatment. Because long-term adminis-
tration of DHEA likely results in follicular atresia,
administration of DHEA to patients, which is aimed
at increasing follicles in cases of primary ovarianTable 1 Serum hormonal level on days 7, 15 and 30 in DHEA-
Day-7 DHEA Day-7 control Day-1
Androstenedione (ng/ml) 0.8 (0.4-0.8) 0.7 (0.5-0.7) 5.6 (3
DHEA-s (ng/dl) 4.5 (3.75-5.25)* < 2* 13 (13
AMH (ng/ml) 9.69 (8.79-10.9) 8.48 (7.83-8.98) 5.11 (
Values: median (IQR); *P < 0.05.insufficiency [27], may have the potential to cause atresia
when administered for long periods.
In our study, we observed weak expression of AMH in
primordial follicles. This is in contrast to two earlier re-
ports, where no AMH expression was observed in prim-
ordial follicles [28,29]. Consistent with our finding,
immunohistochemical staining by Stubbs et al. revealed
expression of AMH in primordial follicles [13]. They
also reported that significantly fewer primordial follicles
stained positively for AMH in PCOS ovaries than non-
PCO ovaries. They suggested that reduced local expos-
ure to AMH would result in a higher proportion of
primordial follicles initiating growth in PCOS. Primor-
dial and early growing follicles lack a direct blood supply
[7], and local paracrine signals play an important part in
regulating initiation of follicle growth [13]. In our study,treated and control rats (Values: median (IQR); *P < 0.05)
5 DHEA Day-15 control Day-30 DHEA Day-30 control
.8-5.6)* 0.2 (0.1-0.5)* 16 (15–21)* 0.3 (0.1-0.3)*
–21)* < 2* 42 (38–72)* < 2*
4.61-6.22)* 3.11 (2.56-3.21)* 1.88 (1.58-2.2) 3.48 (3.26-3.78)
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AMH, which regulates the growth of primordial follicles.
Consequently, androgen-induced AMH expression pro-
vides local negative feedback affecting folliculogenesis
augmented by androgen. The DHEA-treated PCOS
model differs from true PCOS in that regard. The patho-
genesis of PCOS is thought to involve an increase in the
initiation, subsequent growth and arrest of follicle mat-
uration [7]. However, the pathogenesis in the DHEA-
induced PCOS model promotes follicular growth and
atresia regulated by enhanced AMH. Only with
medium-term DHEA administration (increasing follicle
phase) is ovarian morphology in the rat PCOS model
similar to that of true PCOS.
Conclusions
We conclude that medium-term androgen administra-
tion increases the number of follicles in rat ovaries and
enhances production of AMH. However, increased
AMH expression affects early follicles by interfering with
their development. Consequently, long-term androgen
administration leads to a decrease in healthy follicles
and an increase in atretic follicles, which contributes to
ovarian atrophy.
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